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Abstract
Introduction: Continuous renal replacement therapy (CRRT) is a widely used but resource-intensive treatment.
Despite its broad adoption in intensive care units (ICUs), it remains challenging to identify patients who would be
most likely to achieve positive outcomes with this therapy and to provide realistic prognostic information to
patients and families.
Methods: We analyzed a prospective cohort of all 863 ICU patients initiated on CRRT at an academic medical
center from 2008 to 2011 with either new-onset acute kidney injury (AKI) or pre-admission end-stage renal disease
(ESRD). We examined in-hospital and post-discharge mortality (for all patients), as well as renal recovery (for AKI
patients). We identified prognostic factors for both in-hospital and post-discharge mortality separately in patients
with AKI or ESRD.
Results: In-hospital mortality was 61% for AKI and 54% for ESRD. In patients with AKI (n = 725), independent risk
factors for mortality included age over 60 (OR 1.9, 95% CI 1.3, 2.7), serum lactate over 4 mmol/L (OR 2.2, 95% CI 1.5,
3.1), serum creatinine over 3 mg/dL at time of CRRT initiation (OR 0.63, 95% CI 0.43, 0.92) and comorbid liver
disease (OR 1.75, 95% CI 1.1, 2.9). Among patients with ESRD (n = 138), liver disease was associated with increased
mortality (OR 3.4, 95% CI 1.1, 11.1) as was admission to a medical (vs surgical) ICU (OR 2.2, 95% CI 1.1, 4.7).
Following discharge, advanced age became a predictor of mortality in both groups (AKI: HR 1.9, 95% CI 1.2, 3.0;
ESRD: HR 4.1, 95% CI 1.5, 10.9). At the end of the study period, only 25% (n = 183) of patients with AKI achieved
dialysis-free survival.
Conclusions: Among patients initiating CRRT, risk factors for mortality differ between patients with underlying
ESRD or newly acquired AKI. Long-term dialysis-free survival in AKI is low. Providers should consider these factors
when assessing prognosis or appropriateness of CRRT.
Keywords: continuous renal replacement therapy, mortality, acute kidney injury, end stage renal disease, dialysis,
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Introduction
Continuous renal replacement therapy (CRRT) is an
important intervention in critically ill patients with fluid
overload and metabolic disarray who are unable to toler-
ate the hemodynamic shifts of intermittent hemodialysis.
It is expensive and resource intensive, incurring costs of
up to several thousand US dollars per day [1,2]. Mortality
remains high despite theoretical advances in methods
and delivery over the last several years [3-6]. Identifying
patients who would most achieve positive outcomes from
this costly intervention is a particular challenge. In addi-
tion, the decision whether to initiate CRRT is often a
critical juncture during ICU admission, as it often punc-
tuates a time where goals of care and prognosis are revis-
ited by care teams.
Improved assessment of prognosis is essential for guid-
ing medical decision making and optimizing use of limited
resources. Despite several attempts to identify potential
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risk factors for death, there is no widely accepted predic-
tive model [7,8]. Existing analyses have primarily focused
on assessing in-hospital mortality in patients with acute
kidney injury (AKI) requiring CRRT [4,9-11]. In addition
to AKI, however, CRRT is often employed in patients with
pre-existing end-stage renal disease (ESRD) who develop
hemodynamic instability. Few studies have included signif-
icant numbers of patients with ESRD who also received
CRRT [3,12,13]. Furthermore, it may be useful to consider
long-term outcomes in this patient population when con-
sidering the role of CRRT. We sought to address this defi-
cit by identifying risk factors for in-hospital mortality in a
cohort of patients with both AKI and ESRD who received
CRRT, and continued to collect data to assess long-term
outcomes following discharge.
Materials and methods
As part of an internal quality analysis, all adult patients
(age ≥20 years) who received CRRT at Massachusetts
General Hospital (MGH) between 1 January 2008 and 30
September 2011 were followed prospectively after initia-
tion of CRRT. The initial goal of this quality analysis was
to track survival and renal recovery in patients requiring
CRRT, to ensure they were comparable with other institu-
tions. We used the database established as part of this pro-
cess to characterize this patient population and identify
prognostic factors. Patients were excluded if they remained
inpatients at the end of the study period. All clinical and
demographic information was reviewed daily by a regis-
tered nurse in the Division of Nephrology. Information
was obtained from both paper and electronic records.
Interviews with treating clinicians and patients were not
performed.
MGH is a tertiary care hospital with 1,008 beds in
total and 126 ICU beds available for CRRT. CRRT is
provided as continuous veno-venous hemofiltration
using machines from Baxter (Deerfield, IL, USA) or
NxStage Medical (Lawrence, MA, USA) with pre-filter
fluid replacement. Target replacement fluid rates are 20
to 30 mL/kg/hour. Bicarbonate or citrate-based replace-
ment solutions are used. A 1:1 nursing ratio is employed
for all patients on CRRT. Decisions to initiate CRRT are
made by nephrologists in consultation with intensivists.
At this institution, CRRT is performed in lieu of inter-
mittent hemodialysis when patients require vasopressor
support or are considered hemodynamically unstable by
the consulting nephrologist.
ICU and nephrology census data and CRRT machine-
usage logs were reviewed daily to ensure all patients who
had initiated CRRT were included in the study. Laboratory
results closest to the time of CRRT initiation were
recorded from the electronic medical record, including
serum blood urea nitrogen (BUN), creatinine, albumin,
and lactate. Estimated glomerular filtration rate (eGFR)
was calculated using the simplified Modification of Diet in
Renal Disease equation [14]. BUN and creatinine from the
time of admission were also captured for patients without
ESRD at baseline. Demographic and clinical data were
recorded, including age, gender, race, type of ICU, pre-
existing diagnosis of ESRD (all of whom received chronic
hemodialysis therapy prior to admission), length of stay,
and Charlson comorbidity index [15]. In predictive mod-
els, continuous variables were dichotomized based on the
median value to improve interpretability. For values that
were available in both AKI and ESRD populations, med-
ians for the entire population were used for dichotomiza-
tion to allow for comparison between groups. Because the
Charlson index score is a composite measure that incorpo-
rates a wide range of comorbidities, key components of
the score were also examined as independent predictors,
to determine if any particular comorbidity contributed to
outcomes. Although detailed diagnostic information was
not available, ICU type was dichotomized into medical
versus surgical as a surrogate for the admitting diagnosis.
In a randomly selected subset of 40 patients, an additional
chart review was performed to further characterize differ-
ences represented by ICU type.
Patients were followed throughout the study period for
assessment of recovery of renal function and death.
Recovery of renal function was defined as the absence of
ongoing renal replacement therapy (RRT) at the time of
discharge or during the follow up period. In-hospital
mortality was assessed by review of the inpatient electro-
nic medical record. Post-discharge mortality was deter-
mined by review of the outpatient electronic medical
record, public obituaries, and the Social Security Death
Index.
Patients were categorized as having baseline ESRD if
they had a documented history of receiving outpatient
dialysis or had imminent plans to do so. For patients who
had more than one admission requiring CRRT during the
study period, only the first admission was considered in
the analysis.
Ethics statement
The study was approved by the institutional review board
for human subjects at MGH, which waived the require-
ment for informed consent as the data were analyzed
anonymously. All clinical investigation was conducted
according to the principles expressed in the Declaration of
Helsinki.
Statistical methods
STATA 12.1 (StataCorp LP, College Station, TX, USA)
was used for all statistical analysis. Univariate rank sum
and chi square analyses were used for continuous and
categorical variables, respectively. Factors within clinical
subgroups that were statistically significant in univariate
Allegretti et al. Critical Care 2013, 17:R109
http://ccforum.com/content/17/3/R109
Page 2 of 9
models were included in multivariate logistic regression
models of survival to hospital discharge. Where both the
Charlson score and one of its components were significant
univariate predictors, additional multivariate models were
created with only one of these two predictors, to ensure
that colinearity did not mask underlying relationships.
Post-discharge mortality data were assessed using Cox
regression and Kaplan-Meier survival curves with log-rank
testing for significance. As the goal of this study was to
ascertain meaningful outcomes (for example, overall survi-




During the study period, 884 patients were initiated on
CRRT. Six patients under age 20 years, who were in
pediatric ICUs, were excluded. Fifteen patients (1.7% of
the overall population) who underwent CRRT remained
hospitalized at the end of the study period, and thus were
excluded, as outcomes could not be appropriately ascer-
tained. Excluded patients had similar baseline character-
istics to those included in the final analysis. Fourteen
patients had multiple admissions requiring CRRT and
only the first admission was considered for these patients.
After these exclusions, 863 patients remained in the ana-
lysis: 725 with AKI and 138 with ESRD. Demographic
information and comorbidities for this population are
outlined in Table 1. The majority of patients (67%) were
between 50 and 79 years of age; 19% were younger than
50 years and 14% were 80 years or older. The distribution
of ages was similar between AKI and ESRD. A majority of
patients in this study (78%) self-identified as being of
white race. Other reported races included black (5%),
non-black Hispanic (5%), and Asian (3%). The most com-
mon comorbid factors contributing to the Charlson score
included congestive heart failure (31%), diabetes mellitus
(24%) and chronic pulmonary disease (20%).
Compared with the ESRD population, patients with AKI
were less likely to be admitted to a medical ICU (P =
0.001) and tended to have a higher serum lactate (P =
0.05), lower serum albumin (P = 0.002), and lower Charl-
son score (P < 0.001). This population had a lower preva-
lence of diabetes mellitus (P < 0.001), myocardial infarction
(P = 0.002), congestive heart failure (P = 0.004), peripheral
vascular disease (P < 0.001), and cerebrovascular accidents
(P = 0.008). Some laboratory values were not available for
all patients, but were included when measured (n = 624 for
serum lactate, n = 760 for serum albumin). Over 50% of
patients with AKI had a creatinine level below 2 mg/dL on
admission. Serum BUN and creatinine were not analyzed
for patients with ESRD.
Of all patients, 55% were admitted to medical units:
medical ICU (33%), cardiac ICU (20%), neurological
Table 1 Baseline demographics and comorbidities
AKI (n = 725) ESRD (n = 138) P-value
Age, years 63 (53, 74) 66 (54, 76) 0.14
Male 454 (63%) 93 (67%) 0.29
White race 564 (78%) 110 (80%) 0.62
Medical ICU 378 (52%) 93 (67%) 0.001
Lactate, mmol/L 4.3 (1.9, 8.9) 3.2 (1.5, 5.0) 0.05
Albumin, g/dL 2.8 (2.3, 3.2) 3.1 (2.6, 3.4) 0.002
BUN, mg/dL(at admission) 34 (20, 54) N/A N/A
Creatinine, mg/dL(at admission) 1.8 (1.2, 2.9) N/A N/A
BUN, mg/dL(at CRRT initiation) 54 (34, 84) N/A N/A
Creatinine, mg/dL(at CRRT initiation) 3.4 (2.4, 4.7) N/A N/A
Charlson score 2 (1, 4) 5 (4, 6) <0.001
Length of stay, days 21 (10, 38) 19 (9, 32) 0.10
Duration of CRRT, days 5 (3, 10) 4 (3, 8) 0.10
Diabetes mellitus 208 (29%) 75 (54%) <0.001
Chronic pulmonary disease 148 (20%) 23 (17%) 0.31
Liver disease 131 (18%) 19 (14%) 0.22
Malignancy 99 (14%) 14 (10%) 0.26
Myocardial infarction 125 (18%) 40 (29%) 0.002
Congestive heart failure 209 (29%) 57 (42%) 0.004
Peripheral vascular disease 111 (15%) 38 (28%) <0.001
Cerebrovascular accident 91 (13%) 29 (21%) 0.008
Laboratory values used are the closest values to the initiation of CRRT, unless labeled otherwise. Values are median (interquartile range) or number (%). Medical
ICU is defined as admission to a medical ICU (medical, cardiology, neurology) versus non-medical ICU (general surgery, transplant surgery, cardiothoracic surgery,
burn, trauma). AKI, acute kidney injury; ESRD, end-stage renal disease; BUN, blood urea nitrogen; CRRT, continuous renal replacement therapy; NA, not assessed.
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ICU (2%). The remaining patients (45%) were admitted
to surgical units: general surgical ICU (18%), cardiothor-
acic surgical ICU (23%), transplant surgical ICU (3%),
and burn ICU (1%). Compared to medical ICU patients,
patients admitted to the surgical ICU with AKI were
older (65 versus 60 years, P < 0.001), had higher serum
lactate (7.6 versus 5.3 mmol/L, P < 0.001) and lower
serum BUN and creatinine at the time of CRRT initia-
tion (54 versus 69 and 3.3 versus 4.2 mg/dL respectively,
P < 0.001). Fewer of them had liver disease (14% versus
22%, P < 0.001). There was no difference in Charlson
score, albumin, gender, race, or presence of diabetes.
There were no differences in the surgical versus medical
ICU subgroups in patients with ESRD in any of these
categories. Among the 40 patients who were selected for
detailed chart review, we excluded one pediatric patient
who had not been included in the general analysis.
Fifteen of the remaining patients had CRRT initiated in
a medical ICU. Nearly all patients (88%) in surgical
ICUs had an operation during the admission prior to
initiating CRRT; only 13% of medical ICU patients had
preceding surgery. Compared to medical ICU patients,
fewer surgical ICU patients had septic shock (33% ver-
sus 17%); surgical ICU patients also had similar rates of
cardiogenic shock (42% versus 40%) and lower incidence
of preceding cardiac arrest (33% versus 12%). In this
small sample, only the difference in rate of surgery was
statistically significant.
In-hospital mortality
Overall in-hospital mortality for patients with AKI was
60.7% compared with 54.3% in patients with ESRD (P =
0.16). Among patients with AKI, significant predictors
included age over 60 years, lactate greater than 4 mmol/L,
Charlson score over 3, and an underlying diagnosis of liver
disease. Creatinine greater than 3 mg/dL at the time of
CRRT initiation was associated with decreased mortality
(Table 2a). Similarly, lower eGFR at the time of CRRT
initiation was associated with decreased mortality (P =
0.004). Among patients with ESRD, admission to a medi-
cal (versus surgical) ICU, Charlson score over 3, and the
presence of liver disease were predictive of mortality
(Table 2b).
Multivariate logistic regression modeling for in-hospital
mortality was performed using variables that were signifi-
cant in univariate analyses and are summarized in Table 3.
In patients with AKI, all factors significant in univariate
analyses continued to be predictive of mortality with the
exception of Charlson score over 3. In patients with ESRD,
both Charlson score and liver disease lost significance in a
multivariable model. Given the possibility that this was
due to colinearity between these variables, we generated
Table 2 Factors associated with in-hospital mortality among patients with acute kidney injury or end-stage renal
disease
Odds ratio 95% CI P-value
A: Acute kidney injury
Age >60 years 1.6 1.2, 2.2 0.002
Female 0.96 0.71, 1.3 0.82
White race 0.87 0.60, 1.2 0.43
Medical ICU 1.2 0.9, 1.6 0.19
Lactate >4 mmol/L 2.4 1.7, 3.3 <0.001
Albumin >3 g/dL 0.83 0.61, 1.1 0.26
BUN > 30 mg/dL (at admission) 1.1 0.81, 1.5 0.54
Creatinine >2 mg/dL (at admission) 0.76 0.56, 1.0 0.08
BUN >50 mg/dL (at CRRT initiation) 1.3 0.94, 1.7 0.12
Creatinine >3 mg/dL (at CRRT initiation) 0.56 0.41, 0.77 <0.001
Charlson score >3 1.6 1.1, 2.3 0.006
Liver disease 1.8 1.2, 2.8 0.005
B: ESRD
Age >60 years 0.88 0.45, 1.7 0.72
Female 1.2 0.60, 2.5 0.57
White race 0.60 0.25, 1.4 0.24
Medical ICU 2.4 1.1, 4.9 0.02
Lactate >4 mmol/L 1.5 0.28, 7.6 0.65
Albumin >3 g/dL 0.79 0.24, 2.6 0.70
Charlson score >3 2.4 1.0, 5.7 0.05
Liver disease 3.7 1.2, 11.8 0.03
(A) Acute kidney injury (AKI) (n = 725). (B) End-stage renal disease (ESRD) (n = 138). BUN, blood urea nitrogen; CRRT, continuous renal replacement therapy.
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multivariable models with only one of these two predictors
along with ICU type. As liver disease was a stronger pre-
dictor of mortality than Charlson score over 3, this was
included in the final multivariable model (Table 3b).
Post discharge follow-up
A total of 347 patients who survived to hospital dis-
charge were followed until the end of the study period,
with a median follow up of 440 days (IQR 109 to 759).
Among these patients, 28.4% (n = 81 out of 285) of
patients with AKI and 39.7% (n = 25 out of 63) of those
with ESRD died during the follow up period. Age over
60 years was a significant predictor of post-discharge
mortality in both AKI (hazard ratio (HR) 1.9, 95% CI
1.2, 3.0) and ESRD (HR 4.1, 95% CI 1.5, 10.9); Kaplan-
Meier survival curves for age are presented in Figure 1.
Additional risk factors for patients with AKI included
BUN over 30 mg/dL on admission (HR 2.1, 95% CI 1.3,
3.4), BUN at CRRT initiation over 50 mg/dL (HR 2.0,
95% CI 1.3, 3.2), and Charlson score over 3 (HR 2.0,
95% CI 1.3, 3.2).
Among those with AKI who survived until discharge,
89% (n = 255) were no longer dialysis-dependent by
hospital discharge. An additional nine patients eventually
recovered renal function by the end of the study period,
resulting in a total rate of renal recovery of 93%. No
demographic or laboratory data significantly predicted
renal recovery in this subpopulation (see Table 4). In
total, only 25% of patients with AKI (n = 183) achieved
dialysis-free survival by the end of the follow up period
(median follow up 449 days).
Discussion
Because of the lack of conclusive data surrounding out-
comes of patients with either AKI or ESRD who receive
CRRT, we analyzed a prospective cohort of all patients
receiving CRRT at a major academic medical center. We
found that mortality rates were similar between patients
with AKI or ESRD, at 61% and 54%, respectively. We addi-
tionally found that 28% of surviving patients with AKI and
40% of those with ESRD died in the period following dis-
charge, suggesting that in-hospital mortality rates may
underrepresent the impact of CRRT-associated disease on
survival.
In addition to questions about the likelihood of survi-
val, patients and their families often inquire about the
Table 3 Multivariable models identifying factors predictive of in-hospital mortality
Odds ratio 95% CI P-value
A: AKI
Age >60 years 1.9 1.3, 2.7 0.001
Lactate >4 mmol/L 2.2 1.5, 3.1 <0.001
Creatinine >3 mg/dL (at CRRT initiation) 0.63 0.43, 0.92 0.01
Charlson score >3 1.4 0.92, 2.1 0.12
Liver disease 1.75 1.1, 2.9 0.03
B: End-stage renal disease
Medical ICU 2.2 1.1, 4.7 0.03
Liver disease 3.4 1.1, 11.1 0.04

































Figure 1 Kaplan-Meier curves for survival following discharge, by age. Advanced age predicted mortality in patients with either acute
kidney injury (AKI; n = 285) or baseline end-stage renal disease (ESRD; n = 63).
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likelihood of renal recovery when assessing escalation of
care, including CRRT. We found that the rate of renal
recovery among patients with AKI who survived to dis-
charge appeared at first glance to be high (89% at dis-
charge, improving to 93% by the end of the study period),
similar to previously reported rates [9,16]. However, it
may be more appropriate to frame this information as dia-
lysis-free survival; only 25% of all patients with AKI who
required CRRT remained both alive and off dialysis by the
end of the study period. Our study was not intended to
dictate the appropriateness of offering CRRT to a patient
with AKI, but rather to help clinicians frame their goals of
care and prognostic discussions in the most realistic terms.
When examining individual potential predictors of
mortality, we found that risk was modified by several
baseline factors. Furthermore, we found that these risk
factors differed based on whether patients had pre-
admission ESRD, or developed new AKI during the
admission. Whereas other studies have examined both
groups, prior analyses have included smaller numbers of
patients and a wide range of severity of AKI, rather than
an entire population of patients requiring CRRT [12,13].
To our knowledge, this is the largest study to exclusively
examine a CRRT cohort of patients with AKI and ESRD
in parallel. Of particular note, patients with AKI and
ESRD appear to have similar rates of in-hospital mortal-
ity. Depending on the clinical scenario, there may be a
presumption that patients with ESRD are inherently
sicker than those with AKI, and thus would be worse
candidates for CRRT. Our results refute this assertion.
The results also emphasize that these subgroups have
distinct risk factors for mortality.
Among patients in our study with AKI, age over
60 years, serum lactate greater than 4 mmol/L at initiation
of CRRT, and comorbid liver disease were independent
risk factors for mortality. Age may be an indirect baseline
measure of health and ability to recover from critical
illness. Other studies have also identified age as a risk fac-
tor for in-hospital death in severe AKI [9-11,16,17]. The
association of liver disease with the outcomes may reflect
the high mortality associated with hepatorenal syndrome
[18]. An elevated lactate level likely reflects the severity of
the underlying insult, and thus portends a worse outcome.
Interestingly, a creatinine value greater than 3 mg/dL at
initiation of CRRT was associated with lower mortality.
This may reflect the fact that creatinine values represent
underlying muscle mass in addition to renal function.
While eGFR is not a reliable measure of kidney function
in AKI, we used it to reduce the potential confounding
effects of age, race, and gender on creatinine generation.
Analogous to creatinine, we found that lower eGFR was
associated with decreased mortality. Others have sug-
gested that poor baseline renal function in a non-ESRD
population may actually be protective [19,20], supporting
the concept that patients with advanced kidney disease
require a less severe insult to necessitate transition to
CRRT. Additionally, fluid balance may influence creatinine
values in critically ill patients [21]. The association of
higher creatinine with improved outcomes in AKI is intri-
guing, but requires further investigation to understand its
true implications. Surrogate measures of muscle mass
were not collected as part of the routine clinical care of
this cohort, but future studies could explore this associa-
tion more directly. Lastly, scores for the assessment of the
severity of illness, such as the acute physiology and
chronic health evaluation (APACHE) II or sequential
organ failure assessment (SOFA) score were not used
clinically and thus, were unavailable in our analysis. These
could be studied in prospective analyses that calculate
these scores.
Predictors of mortality in ESRD were strikingly differ-
ent from those in AKI. This may reflect the different
pathways by which these two populations come to be
treated with CRRT. A patient with ESRD has a baseline
Table 4 Odds of requiring ongoing dialysis at discharge among surviving patients with acute kidney injury (n = 285)
Odds ratio 95% CI P-value
Age >60 years 1.8 0.81, 3.9 0.15
Female 0.80 0.36, 1.8 0.59
White race 1.3 0.49, 3.7 0.57
Medical ICU 1.6 0.76, 3.5 0.21
Lactate >4 mmol/L 0.91 0.32, 2.6 0.85
Albumin >3 g/dL 0.82 0.36, 1.9 0.64
BUN > 30 mg/dL (at admission) 1.7 0.76, 3.8 0.20
Creatinine >2 mg/dL (at CRRT admission) 1.3 0.63, 2.9 0.44
BUN >50 mg/dL (at CRRT initiation) 1.7 0.78, 3.7 0.18
Creatinine >3 mg/dL (at CRRT initiation) 2.1 0.83, 5.3 0.12
Charlson score >3 1.5 0.65, 3.4 0.35
BUN, blood urea nitrogen; CRRT, continuous renal replacement therapy.
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requirement for RRT and thus, only requires a superim-
posed hemodynamic insult in order to require CRRT.
Relatively mild perioperative hypotension in the absence
of severe illness might be adequate to cause a patient
with ESRD to end up on CRRT in a surgical ICU. In
contrast, a medical ICU admission would more likely to
be associated with a significant systemic insult (for
example, septic shock). A patient with AKI, on the other
hand, requires an insult sufficient to cause both kidney
injury and hemodynamic compromise. A recent review
examining ICU admissions among patients with ESRD
showed that these patients may have favorable short- and
long-term outcomes compared to those with AKI [22].
Our data support the conclusion that these groups should
be viewed distinctly, and that our current illness severity
scores may not be equally valid in both populations.
In the general ICU population, long-term post-discharge
survival has been well described. One-year mortality rates
in those who survive to ICU discharge have been reported
between 5 and 15% [23,24], with certain disease processes,
such as ARDS and sepsis, conveying poorer long term
prognoses [25-29]. In AKI, few studies have examined the
long-term effects of illnesses requiring CRRT. Those that
have are limited by having only one year of follow up or
less, and have included inconsistent patient subgroups,
such as exclusively surgical patients [30,31], patients on
either CRRT or intermittent hemodialysis [16,20,31], and
severe AKI that did not necessarily require renal replace-
ment [32]. Similarly, there are few studies of long-term
outcomes in ESRD, but these have not focused on patients
receiving CRRT [3,32-34]. Prior literature echoes some of
our findings in AKI, identifying long-term predictors of
mortality that include age [16,30-32], high Charlson score
[16,20], and medical diagnosis [32]. We also found that
elevated BUN, both at admission and initiation of CRRT,
were predictive of post-discharge mortality, in contrast to
the protective association of an elevated creatinine in the
inpatient settings. This may reflect the unique association
of creatinine with muscle mass. Interestingly, in ESRD, age
was a predictor of post-discharge mortality, but not inpati-
ent mortality. This may reflect the broad range of disease
severity that leads to initiation of CRRT in the hospital,
while baseline health (as reflected by age) is more impor-
tant in the outpatient setting. Indeed, prior literature sug-
gests that in patients with ESRD, the risk of mortality may
return to the pre-ICU admission baseline risk within
6 months of discharge [22,32-34].
By its observational design, we were limited by the
laboratory data available to the treating clinicians for each
patient. As a result, we could not investigate potential
novel predictors of mortality. Volume overload has been
associated with worse in-hospital and post-discharge out-
comes, but was not quantified in our dataset [35-37].
Additional factors, such as urine output, chronic kidney
disease (CKD) stage among patients in the AKI group pre-
hospitalization, reason for CRRT initiation, and dialysis
vintage in the ESRD group, could be captured prospec-
tively in future studies. Efficacy measures for CRRT, such
as metabolic control and downtime could also clarify
potential mediators or effect modifiers.
Because there were no coded admitting diagnoses avail-
able in this database, we used admission to medical versus
surgical ICU as a proxy for underlying disease process.
This yields both limitations and benefits to our conclu-
sions: the admitting diagnosis is often subjective, especially
in complex ICU patients with multi-system organ dysfunc-
tion, as it is not always possible to determine if one disease
process is the culprit for renal failure. Given our database
size, it is unlikely that individual diagnoses would have
obtained sufficient power to provide statistically significant
results. In a detailed review of medical records from a sub-
set of patients in this study, we unsurprisingly found that
patients in surgical ICUs were considerably more likely to
be postoperative and somewhat less likely to have septic
shock.
Admission to a medical ICU predicted in-hospital mor-
tality only in patients with ESRD. We found no differences
between surgical and medical ICU patients in age, race,
gender, Charlson score, serum albumin, or serum lactate,
making it unlikely that these factors confounded the rela-
tionship between ICU type and mortality.
As both the decision regarding the timing of the initia-
tion and the type of RRT is subjective and affected by both
resources and underlying disease, this single-center study
may not be completely generalizable to sites with different
practice patterns or patient populations. However, most of
the key demographics for this population, such as age and
race, were consistent with prior reports [9,32]. Because of
the small number of patients who survived to discharge,
we had less power to identify predictors of renal recovery
and mortality post discharge. Given the observational
design that precluded direct confirmation of patient mor-
tality, it is possible that we underestimated post-discharge
mortality. However, in contrast to other studies where fol-
low up was more restricted, we were able to provide nearly
4 years of rolling post-discharge data.
Conclusions
Patients undergoing CRRT with AKI and ESRD have dif-
ferent risk factors for mortality, both in the short and long
term. Mortality is high in both groups, even among
patients who survive to hospital discharge. Patients with
ESRD should not be inherently considered poor candi-
dates for CRRT when compared to those with AKI. The
vast majority of patients with AKI who receive CRRT will
not achieve long-term dialysis-free survival. Clinicians
should be aware of these statistics (for example, 25% likeli-
hood of dialysis-free survival in AKI patients started on
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CRRT) when counseling patients and their families.
Further studies could assess the impact of this information
on medical decision making, validate the results of this
study in additional centers, and assess health-related qual-
ity of life among survivors.
Key Messages
• In-hospital mortality is approximately 60%, both
for patients with AKI and ESRD
• Predictors of mortality differ between these groups,
likely reflecting differences in the clinical processes
that lead to CRRT initiation
• While the frequency of renal recovery among sur-
vivors with AKI exceeds 89%, high rates of mortality
before and after discharge result in an overall dialy-
sis-free survival rate of only 25% (with a median fol-
low up of 449 days)
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